Cargando…
Multiple Phenotypic Conversion in Malignant Melanoma: Obtainment of Granulocyte Colony-Stimulating Factor-Producing Ability during the Intermission of Nivolumab Therapy
Malignant melanoma (MM) is one of the most aggressive, recalcitrant, and recurrence-prone skin neoplasms. Its feature is likely to be associated with phenotypic conversion due to tumor heterogeneity. The multidisciplinary assessment, including surgery, drug therapy using anticancer agents and immune...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210021/ https://www.ncbi.nlm.nih.gov/pubmed/35813695 http://dx.doi.org/10.1159/000524827 |
_version_ | 1784730068779532288 |
---|---|
author | Chujo, Satomi Nobeyama, Yoshimasa Asahina, Akihiko Itoh, Munenari |
author_facet | Chujo, Satomi Nobeyama, Yoshimasa Asahina, Akihiko Itoh, Munenari |
author_sort | Chujo, Satomi |
collection | PubMed |
description | Malignant melanoma (MM) is one of the most aggressive, recalcitrant, and recurrence-prone skin neoplasms. Its feature is likely to be associated with phenotypic conversion due to tumor heterogeneity. The multidisciplinary assessment, including surgery, drug therapy using anticancer agents and immune checkpoint inhibitors, and radiotherapy, is needed for the treatment of advanced MM. Herein, we report a long-term follow-up MM, in which multiple phenotypic conversion occurred during several treatments. In particular, our case obtained granulocyte colony-stimulating factor-producing ability during the intermission of nivolumab therapy and it was successfully controlled by re-administration of nivolumab. Sharing the case having a varied clinical course is meaningful to increase the knowledge and decision branches for the treatment of melanoma. |
format | Online Article Text |
id | pubmed-9210021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-92100212022-07-08 Multiple Phenotypic Conversion in Malignant Melanoma: Obtainment of Granulocyte Colony-Stimulating Factor-Producing Ability during the Intermission of Nivolumab Therapy Chujo, Satomi Nobeyama, Yoshimasa Asahina, Akihiko Itoh, Munenari Case Rep Oncol Case Report Malignant melanoma (MM) is one of the most aggressive, recalcitrant, and recurrence-prone skin neoplasms. Its feature is likely to be associated with phenotypic conversion due to tumor heterogeneity. The multidisciplinary assessment, including surgery, drug therapy using anticancer agents and immune checkpoint inhibitors, and radiotherapy, is needed for the treatment of advanced MM. Herein, we report a long-term follow-up MM, in which multiple phenotypic conversion occurred during several treatments. In particular, our case obtained granulocyte colony-stimulating factor-producing ability during the intermission of nivolumab therapy and it was successfully controlled by re-administration of nivolumab. Sharing the case having a varied clinical course is meaningful to increase the knowledge and decision branches for the treatment of melanoma. S. Karger AG 2022-05-30 /pmc/articles/PMC9210021/ /pubmed/35813695 http://dx.doi.org/10.1159/000524827 Text en Copyright © 2022 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Chujo, Satomi Nobeyama, Yoshimasa Asahina, Akihiko Itoh, Munenari Multiple Phenotypic Conversion in Malignant Melanoma: Obtainment of Granulocyte Colony-Stimulating Factor-Producing Ability during the Intermission of Nivolumab Therapy |
title | Multiple Phenotypic Conversion in Malignant Melanoma: Obtainment of Granulocyte Colony-Stimulating Factor-Producing Ability during the Intermission of Nivolumab Therapy |
title_full | Multiple Phenotypic Conversion in Malignant Melanoma: Obtainment of Granulocyte Colony-Stimulating Factor-Producing Ability during the Intermission of Nivolumab Therapy |
title_fullStr | Multiple Phenotypic Conversion in Malignant Melanoma: Obtainment of Granulocyte Colony-Stimulating Factor-Producing Ability during the Intermission of Nivolumab Therapy |
title_full_unstemmed | Multiple Phenotypic Conversion in Malignant Melanoma: Obtainment of Granulocyte Colony-Stimulating Factor-Producing Ability during the Intermission of Nivolumab Therapy |
title_short | Multiple Phenotypic Conversion in Malignant Melanoma: Obtainment of Granulocyte Colony-Stimulating Factor-Producing Ability during the Intermission of Nivolumab Therapy |
title_sort | multiple phenotypic conversion in malignant melanoma: obtainment of granulocyte colony-stimulating factor-producing ability during the intermission of nivolumab therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210021/ https://www.ncbi.nlm.nih.gov/pubmed/35813695 http://dx.doi.org/10.1159/000524827 |
work_keys_str_mv | AT chujosatomi multiplephenotypicconversioninmalignantmelanomaobtainmentofgranulocytecolonystimulatingfactorproducingabilityduringtheintermissionofnivolumabtherapy AT nobeyamayoshimasa multiplephenotypicconversioninmalignantmelanomaobtainmentofgranulocytecolonystimulatingfactorproducingabilityduringtheintermissionofnivolumabtherapy AT asahinaakihiko multiplephenotypicconversioninmalignantmelanomaobtainmentofgranulocytecolonystimulatingfactorproducingabilityduringtheintermissionofnivolumabtherapy AT itohmunenari multiplephenotypicconversioninmalignantmelanomaobtainmentofgranulocytecolonystimulatingfactorproducingabilityduringtheintermissionofnivolumabtherapy |